ASCO 2022

ASCO 2022
June 03-07, 2022
Chicago, IL

American Society of Clinical Oncology 2022.

Explore more information for Gilead Oncology therapies
Results (8)

Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results

Impact of magrolimab treatment in combination with azacitidine on red blood cells in higher-risk myelodysplastic syndrome (HR-MDS) patients

Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 Phase 1b study results

Primary Results From TROPiCS-02: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients With Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced Breast Cancer

Exposure-Response Analyses of Sacituzumab Govitecan (SG) Efficacy and Safety in Patients (Pts) With Metastatic Triple-Negative Breast Cancer (mTNBC)

Trial in Progress: EVOKE-02: A phase 2 study of sacituzumab govitecan plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non−small-cell lung cancer (NSCLC)

Trial in Progress: EVOKE-01: A phase 3 study of sacituzumab govitecan (SG) vs docetaxel in patients with non-small cell lung cancer (NSCLC) progressing on or after platinum-based chemotherapy and checkpoint inhibitors